MCC and cystic fibrosis: As more sophisticated CF animal models have become available that spontaneously exhibit defects in MCC (3, 31, 32), this points to the need to assess the impact of ENaC inhibition on downstream defects of CF pathophysiology in these systems, including mucus clearance (3, 33, 34).